The statements below are read from EP BIOCOMPOSITES LIMITED’s filed results, 3 filed quarters and 6 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 26, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 7.60 | 4.07 | 9.57 | +25.8% |
| 6.31 | 3.83 | 7.57 | +19.9% | |
| Operating profit | 1.29 | 0.24 | 1.99 | +54.8% |
| OPM % | 16.9% | 6.0% | 20.8% | +3.9 pp |
| Other income | 0.06 | 0.07 | 0.07 | +10.8% |
| Interest | 0.19 | 0.15 | 0.19 | +2.4% |
| Depreciation | 0.06 | 0.05 | 0.05 | -5.4% |
| Profit before tax | 1.11 | 0.12 | 1.82 | +64.2% |
| Tax % | 25.4% | 25.2% | 24.7% | -0.7 pp |
| Net profit | 0.83 | 0.09 | 1.37 | +65.8% |
| EPS (₹) | 4.91 | 0.51 | 0.00 | -100.0% |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
